WELCOME TO ARTARA
We are a team of veteran rare disease specialists, passionate about bringing therapies to patients who have no current treatment options.
We work with academic and industry partners around the world to find and develop breakthrough therapies that will improve the well-being of people with rare, neglected, and serious diseases.
PATIENTS AT THE HEART OF WHAT WE DO
EXCELLENCE AND EFFICIENCY
BE A FORCE FOR GOOD
Lymphatic Malformations (LMs)
Our lead pipeline program, TARA-002, is a toll-like receptor 4 agonist for the treatment of lymphangiomas (Lymphatic Malformations).
Lymphatic malformations are localized anomalies of the lymphatic vasculature that develop in utero or in infants, most commonly in the head and neck. Currently, the only approved treatment for LMs in the US and Europe is surgical excision, which carries high rates of recurrence and surgical complications.
TARA-002 is an investigational cellular therapy based on OK-432, an immunostimulant, currently approved in Japan and Taiwan, that has been the standard of care for LMs for over 20 years. A randomized, Phase-2 study of OK-432, from the University of Iowa, demonstrated a clinically successful outcome in 94% of patients with macrocystic LMs and 63% of patients with mixed macrocystic-microcystic LMs.
IV CHOLINE CHLORIDE
INTESTINAL FAILURE ASSOCIATED LIVER DISEASE (IFALD)
Our first program is IV Choline Chloride, a first-in-class treatment for the orphan disease Intestinal Failure Associated Liver Disease (IFALD).
IFALD is a potentially fatal liver disease that afflicts people who survive on parenteral nutrition (PN). Through PN, patients with a missing or non-functioning gastrointestinal tract receive most or all the nutrition needed to support life.
Up to 65% of all PN patients develop IFALD because of deficiencies and imbalances in PN ingredients, and the abnormal way those PN nutrients are used by the body.
Many patients with IFALD eventually need a dual liver/small intestine transplant to survive, one of the costliest and risky surgical procedures performed.
IV Choline Chloride reversed signs of IFALD in two promising efficacy studies.